Higher cardiovascular risk observed with beta-blockers in CKD patients without prior cardiovascular disease

Clicks: 3
ID: 317168
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #104 of 129 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 129 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Chronic kidney disease (CKD) is strongly linked to cardiovascular disease (CVD) risk. Although beta-blockers (BBs) are widely used for CVD prevention, their effectiveness and safety in CKD patients without established CVD remain uncertain. Methods We conducted a nationwide cohort study using Korean health insurance data. CKD patients without established CVD between 2012 and 2015 were identified based on an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 on at least two occasions. BB users were defined as those prescribed BBs for ≥ 6 months. Primary outcomes were all-cause mortality and 4-point major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, stroke, and hospitalization for heart failure. A 1:2 propensity score matching was performed, and Cox proportional hazards models were applied. Subgroup analyses were also conducted by eGFR category and BB agents. Results After matching, 9,067 BB users and 17,094 non-users were included. BB use was associated with increased risks of all-cause mortality (hazard ratio [HR], 2.09; 95% confidence interval [CI], 1.96–2.24) and MACE (HR, 1.33; 95% CI, 1.26–1.41). The increased risks were consistent across individual outcomes, including CV death (HR 2.07; 95% CI, 1.66–2.57), myocardial infarction (HR 1.29; 95% CI, 1.13–1.46), stroke (HR 1.21; 95% CI 1.13–1.31), and heart failure hospitalization (HR 1.58; 95% CI, 1.44–1.72). Subgroup analysis showed greater mortality risk at lower eGFR levels and a higher risk of adverse events with carvedilol compared with other BBs. Conclusions Among CKD patients without established CVD, BB use was associated with increased mortality and cardiovascular risk. Further studies are needed to clarify whether these associations reflect treatment effects or underlying patient risk.
Reference Key
openalex_W7164590455 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Seung Hyun Han, Mina Kim, Jungkuk lee, Sang Youb Han
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag204
URL
https://doi.org/10.1093/ckj/sfag204
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.